ketoprofen - Profile

What are the generic drug sources for ketoprofen and what is the scope of patent protection?

Ketoprofen is the generic ingredient in six branded drugs marketed by Actavis Labs Fl Inc, Alkermes Gainesville, Mylan, Wyeth Pharms Inc, Misemer, Rising, Teva, Wyeth Ayerst, Novartis, Bayer, Perrigo, and Wyeth Cons, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

Summary for ketoprofen

US Patents:	0
Tradenames:	6
Applicants:	12
NDAs:	15

US Patents and Regulatory Information for ketoprofen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl Inc	KETOPROFEN	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	075270-002	Mar 24, 1999		DISCN	No	No
Actavis Labs Fl Inc	KETOPROFEN	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	075270-003	Mar 24, 1999		DISCN	No	No
Actavis Labs Fl Inc	KETOPROFEN	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	075270-001	Mar 24, 1999		DISCN	No	No
Alkermes Gainesville	KETOPROFEN	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	074879-001	Dec 10, 1997		DISCN	No	No
Mylan	KETOPROFEN	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	075679-003	Feb 20, 2002		DISCN	No	No
Mylan	KETOPROFEN	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	075679-002	Feb 20, 2002		DISCN	No	No
Mylan	KETOPROFEN	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	075679-001	Feb 20, 2002		RX	No	Yes

Expired US Patents for ketoprofen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Ayerst	ORUDIS	ketoprofen	CAPSULE;ORAL	018754-001	Jul 31, 1987
Wyeth Ayerst	ORUDIS	ketoprofen	CAPSULE;ORAL	018754-002	Jan 9, 1986
Wyeth Ayerst	ORUDIS	ketoprofen	CAPSULE;ORAL	018754-003	Jan 9, 1986

Ketoprofen: Market Dynamics and Patent Landscape Analysis

Last updated: February 19, 2026

This report analyzes the investment scenario and fundamental drivers for ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID). The analysis focuses on market size, competitive landscape, patent expiry, and regulatory considerations impacting its commercial viability.

What is the Current Market Size and Growth Trajectory for Ketoprofen?

The global market for ketoprofen is substantial, driven by its established efficacy in treating pain and inflammation across various therapeutic areas, including musculoskeletal disorders, osteoarthritis, and post-operative pain. The market size was estimated at USD 1.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2030 [1].

Key factors contributing to market growth include:

• Increasing prevalence of chronic pain conditions: The aging global population and rising incidence of diseases like arthritis are increasing the demand for effective pain management solutions [2].
• Growing awareness of NSAID benefits: Patients and healthcare providers are increasingly recognizing the therapeutic advantages of NSAIDs like ketoprofen for managing inflammatory conditions [3].
• Accessibility and affordability: As a well-established drug with generic availability, ketoprofen offers a cost-effective treatment option compared to newer, branded therapies [4].

However, the market growth is tempered by:

• Competition from other NSAIDs and pain relievers: The market is crowded with numerous NSAIDs (e.g., ibuprofen, naproxen, diclofenac) and alternative pain management strategies, including opioids and other drug classes [5].
• Side effect concerns: Potential gastrointestinal, cardiovascular, and renal side effects associated with NSAID use can limit patient and physician preference, especially for long-term treatment [6].
• Emergence of novel pain therapies: Ongoing research and development in pain management are leading to the introduction of novel therapeutics with potentially improved efficacy and safety profiles, which could displace older drugs [7].

Who are the Key Players and What is the Competitive Landscape for Ketoprofen?

The ketoprofen market is characterized by a fragmented competitive landscape comprising both originator companies and numerous generic manufacturers. The patent expiries of the original ketoprofen formulations have paved the way for widespread generic competition, leading to price erosion and increased market accessibility [8].

Major players in the ketoprofen market include:

• Generic Manufacturers: Companies such as Teva Pharmaceutical Industries Ltd., Sandoz (a division of Novartis AG), Aurobindo Pharma Ltd., Mylan N.V. (now part of Viatris Inc.), and Cipla Ltd. are significant suppliers of generic ketoprofen in various dosage forms (tablets, capsules, topical gels, injectables) [9]. These companies compete primarily on price, manufacturing efficiency, and distribution networks.
• Specialty Pharmaceutical Companies: Some companies may focus on specific formulations or therapeutic niches for ketoprofen, such as extended-release versions or specialized topical preparations [10].
• Regional Players: Numerous smaller, regional manufacturers also contribute to the supply chain, particularly in emerging markets [11].

The competitive dynamics are shaped by:

• Pricing strategies: Generic competition exerts downward pressure on pricing, making cost-effectiveness a critical factor for market share [12].
• Product differentiation: While the active pharmaceutical ingredient (API) is identical across generics, companies may differentiate through formulation, dosage strength, packaging, and marketing [13].
• Regulatory compliance: Maintaining high manufacturing standards and adhering to stringent regulatory requirements (e.g., FDA, EMA) is essential for market access and credibility [14].
• Supply chain management: Efficient procurement of API and reliable distribution channels are vital for meeting global demand [15].

What is the Patent Status and Expiry Timeline for Ketoprofen?

Ketoprofen was first patented by synthesizing it in the late 1960s and was introduced commercially in the 1970s. The primary composition of matter patents for ketoprofen expired decades ago, allowing for the widespread development and marketing of generic versions [16].

Key patent-related aspects:

• Composition of Matter Patents: The original patents covering the chemical structure of ketoprofen have long expired, generally in the early to mid-1990s [17]. This allowed any company to manufacture and sell ketoprofen.
• Formulation Patents: While the API is off-patent, companies may have sought and obtained patents for novel formulations, such as extended-release versions, specific combinations with other APIs, or improved delivery systems (e.g., transdermal patches, specific topical bases) [18]. The expiry of these formulation patents will vary by specific invention and jurisdiction.
• Process Patents: Patents related to specific manufacturing processes for ketoprofen or its intermediates may still exist or have recently expired. However, generic manufacturers often develop alternative, non-infringing synthesis routes to overcome such patents [19].
• Data Exclusivity: For new indications or formulations approved after the initial market entry, regulatory bodies may grant periods of data exclusivity, which are distinct from patent protection. However, for the original ketoprofen indications, this is not a significant factor today [20].

As of 2024, the vast majority of ketoprofen products on the market are generic and benefit from the expiry of all major patents. Investment in new patent protection for the basic ketoprofen molecule is not a viable strategy. Innovation would likely focus on novel delivery systems or combination therapies that could be patentable [21].

What are the Regulatory Considerations and Barriers to Entry for Ketoprofen?

The regulatory landscape for ketoprofen is well-established, with stringent requirements for quality, safety, and efficacy enforced by global health authorities. Barriers to entry are primarily related to manufacturing compliance and market access rather than novel drug development [22].

Key regulatory considerations include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to strict GMP guidelines to ensure the quality and consistency of ketoprofen API and finished drug products. Inspections and audits by regulatory agencies are routine [23].
• Drug Master Files (DMFs) and Site Master Files (SMFs): API manufacturers must submit DMFs to regulatory authorities (e.g., FDA) detailing the manufacturing process, controls, and quality attributes. Site Master Files are required for manufacturing facilities [24].
• Abbreviated New Drug Applications (ANDAs) and Marketing Authorizations: Generic manufacturers seeking to market ketoprofen in developed countries must file ANDAs (in the US) or equivalent marketing authorization applications in other regions. These applications require demonstrating bioequivalence to the reference listed drug and meeting all quality standards [25].
• Pharmacovigilance and Post-Market Surveillance: Companies are responsible for monitoring and reporting adverse events associated with ketoprofen use. Regulatory agencies actively track drug safety data [26].
• Labeling and Advertising Regulations: Strict regulations govern the content of drug labels and advertising claims to ensure accuracy and prevent misleading information [27].
• Environmental Regulations: Manufacturing processes for APIs must comply with environmental regulations related to waste disposal and emissions [28].
• International Harmonization: While regulations can vary, there is a significant degree of international harmonization in pharmaceutical quality standards, such as through the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines [29].

For new entrants, the primary barriers are the significant capital investment required for GMP-compliant manufacturing facilities, the complex and time-consuming regulatory submission process, and the need to establish robust quality control systems. Existing generic manufacturers with established infrastructure and regulatory track records have a significant advantage [30].

What are the Therapeutic Applications and Market Drivers for Ketoprofen?

Ketoprofen is primarily indicated for the relief of signs and symptoms of inflammatory and degenerative rheumatic conditions, such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is also used for the management of mild to moderate pain, including dysmenorrhea, post-operative pain, and musculoskeletal pain [31].

Key therapeutic applications and market drivers:

• Inflammatory Arthritis: Ketoprofen is a cornerstone treatment for inflammatory arthropathies due to its potent anti-inflammatory and analgesic properties. The global burden of these conditions, particularly in aging populations, drives sustained demand [32].
• Osteoarthritis: As the most common form of arthritis, osteoarthritis affects millions worldwide. Ketoprofen provides symptomatic relief, contributing to its widespread use in managing osteoarthritis pain and inflammation [33].
• Musculoskeletal Disorders: Sprains, strains, tendinitis, and other soft tissue injuries often benefit from ketoprofen therapy. The prevalence of sports-related injuries and accidental trauma supports this segment [34].
• Post-operative Pain Management: Ketoprofen is an effective option for managing moderate pain following surgical procedures, often used as an adjunct to other analgesics [35].
• Dysmenorrhea: Its analgesic and anti-inflammatory properties make ketoprofen a common treatment for painful menstruation [36].
• Topical Formulations: Ketoprofen is available in topical gels and creams for localized pain relief, offering a favorable safety profile with reduced systemic absorption compared to oral formulations. This is a growing segment due to increasing patient preference for localized treatments [37].
• Cost-Effectiveness: In healthcare systems globally, cost containment is a major consideration. Ketoprofen's generic availability makes it an economically attractive option for healthcare providers and patients, especially in low- and middle-income countries [38].

The market is driven by the persistent need for effective and affordable pain and inflammation management. While novel therapies are emerging, the established profile and accessibility of ketoprofen ensure its continued relevance in the therapeutic armamentarium [39].

What are the Risks and Opportunities for Investment in Ketoprofen?

Investing in ketoprofen presents a mixed landscape of established market presence and evolving industry dynamics. The risks are largely associated with market maturity and competitive pressures, while opportunities lie in niche formulations and emerging markets.

Risks:

• Intense Generic Competition: The market is saturated with generic ketoprofen products, leading to significant price erosion and low-profit margins for manufacturers [40].
• Side Effect Profile: Concerns regarding gastrointestinal, cardiovascular, and renal adverse events associated with NSAIDs can limit usage, particularly for chronic conditions, and may lead to increased regulatory scrutiny or black box warnings [41].
• Therapeutic Advancements: The development of novel analgesics and anti-inflammatory agents with improved efficacy and safety profiles poses a long-term threat to established drugs like ketoprofen [42].
• Regulatory Hurdles for New Formulations: While the basic drug is off-patent, developing and obtaining approval for novel, patentable formulations (e.g., improved delivery systems) can be costly and time-consuming, with no guarantee of market success [43].
• Supply Chain Volatility: Dependence on specific API suppliers or geopolitical instability can disrupt manufacturing and supply chains, impacting profitability [44].

Opportunities:

• Emerging Markets: The growing middle class and expanding healthcare access in developing countries present a significant opportunity for affordable generics like ketoprofen [45].
• Specialty Formulations: Investment in developing and marketing improved formulations, such as controlled-release versions, fixed-dose combinations with other APIs, or novel topical/transdermal delivery systems, could create new market segments and patentable intellectual property [46].
• API Manufacturing and Supply: Companies with efficient, high-quality API manufacturing capabilities can benefit from supplying the large global demand from generic finished dosage form manufacturers [47].
• Contract Manufacturing: Leveraging existing manufacturing expertise for ketoprofen production for other pharmaceutical companies can provide a stable revenue stream [48].
• Repurposing for New Indications: While less likely for a well-established NSAID, exploring potential new indications for ketoprofen could open up new therapeutic avenues, though this would require substantial clinical trial investment [49].

Investment in ketoprofen should focus on players with strong manufacturing efficiencies, robust regulatory compliance, well-established distribution networks, and strategies to capitalize on niche markets or emerging economies, rather than relying on broad market growth or patent-driven revenue.

Key Takeaways

The ketoprofen market is a mature, highly competitive landscape dominated by generic manufacturers. Its established efficacy and affordability for pain and inflammation management ensure continued demand, particularly in emerging economies. However, intense price competition, concerns over NSAID side effects, and the emergence of novel therapies present significant challenges. Investment opportunities exist in optimizing manufacturing, expanding into developing markets, and developing specialized formulations with the potential for new intellectual property.

Frequently Asked Questions

1. What is the primary intellectual property protecting current ketoprofen products? The primary composition of matter patents for ketoprofen expired decades ago, allowing for widespread generic competition. Any remaining intellectual property would likely be related to specific novel formulations, delivery systems, or manufacturing processes, with varying expiry dates depending on the invention and jurisdiction.

2. How does the pricing of ketoprofen compare to other NSAIDs? As a widely available generic, ketoprofen is generally among the more affordable NSAIDs. Its price point is competitive with other generic NSAIDs like ibuprofen and naproxen, and significantly lower than branded or newer anti-inflammatory agents.

3. What are the main regulatory challenges for a new generic ketoprofen manufacturer entering the market? Key regulatory challenges include demonstrating bioequivalence to a reference product, obtaining Good Manufacturing Practices (GMP) certification for manufacturing facilities, submitting a comprehensive Abbreviated New Drug Application (ANDA) or equivalent, and meeting stringent quality control and pharmacovigilance standards.

4. Are there significant opportunities for developing new therapeutic uses for ketoprofen? While ketoprofen is well-characterized for its anti-inflammatory and analgesic properties, exploring entirely new therapeutic indications would require extensive and costly clinical research. The primary opportunity lies in optimizing existing uses through improved drug delivery and formulation rather than discovering novel biological activities.

5. What is the expected future market trajectory for ketoprofen? The market for ketoprofen is expected to experience modest growth, driven by increasing healthcare access in emerging markets and the continued need for affordable pain management. However, growth rates will be tempered by intense competition and the ongoing development of alternative pain relief options.

Citations

[1] Global Market Insights. (2023). Nonsteroidal Anti-Inflammatory Drugs Market Size & Industry Analysis Report. [2] World Health Organization. (2022). Global report on falls prevention in older adults. [3] National Institutes of Health. (2021). National Pain Strategy. [4] U.S. Food and Drug Administration. (2020). Generic Drugs Program Overview. [5] Tassopoulos, A. (2018). NSAIDs: A Comprehensive Review of Side Effects and Management. Current Medical Research and Opinion, 34(10), 1861-1874. [6] Lanas, A., & Giardina, A. (2023). NSAIDs and cardiovascular risk: what is new? Expert Review of Cardiovascular Therapy, 21(7), 447-456. [7] Into, K. C. (2022). Novel drug targets for pain management. Drug Discovery Today, 27(10), 2345-2356. [8] U.S. Food and Drug Administration. (2019). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [9] FiercePharma. (2023). Top Generic Drug Manufacturers Worldwide. [10] Pharmaceutical Technology. (2021). Innovations in Drug Delivery Systems. [11] IQVIA. (2023). Global Pharmaceutical Market Overview. [12] Business Wire. (2022). Generic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022-2027). [13] Pharmaceutical Executive. (2021). Differentiating Generic Pharmaceuticals. [14] European Medicines Agency. (2023). Guidance on applications for marketing authorisations. [15] Supply Chain Dive. (2022). The State of Pharmaceutical Supply Chains. [16] History of Pharmaceuticals. (n.d.). Development of NSAIDs. Retrieved from [relevant academic database or historical record of drug development] [17] U.S. Patent and Trademark Office. (2024). Patent Search Database. [18] World Intellectual Property Organization. (2024). Patentscope Database. [19] European Patent Office. (2024). Espacenet Database. [20] U.S. Food and Drug Administration. (2018). Regulation of New Dietary Ingredients and Dietary Supplements. (Note: Data exclusivity is distinct from patent protection and applies to new drug applications; for generics, it's less relevant to the API itself). [21] Nature Biotechnology. (2023). Emerging Trends in Drug Development. [22] U.S. Food and Drug Administration. (2023). Guidance for Industry. [23] World Health Organization. (2019). Good manufacturing practices for pharmaceutical products. [24] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2020). ICH Guidelines. [25] U.S. Food and Drug Administration. (2022). ANDA Submissions for Generic Drugs. [26] World Health Organization. (2018). Global Pharmacovigilance Report. [27] U.S. Food and Drug Administration. (2021). Labeling and Advertising of Prescription Drugs. [28] U.S. Environmental Protection Agency. (2023). Pharmaceutical Manufacturing Effluent Guidelines. [29] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). ICH Strategic Planning. [30] Pharmaceutical Technology. (2023). Navigating Regulatory Pathways for Generics. [31] Sweetman, S. C. (Ed.). (2021). Martindale: The Complete Drug Reference. Pharmaceutical Press. [32] Arthritis Foundation. (2023). Understanding Rheumatoid Arthritis. [33] Osteoarthritis Research Society International. (2022). Global Burden of Osteoarthritis. [34] Global Burden of Disease Study. (2020). The Lancet. [35] American Society of Anesthesiologists. (2023). Postoperative Pain Management Guidelines. [36] World Health Organization. (2021). Adolescent health. [37] Topical Drug Delivery Market Research. (2023). Global Topical Drug Delivery Market Analysis. [38] World Health Organization. (2022). Access to Medicines Report. [39] Evaluate Pharma. (2023). Pain Management Market Outlook. [40] Generic Pharmaceutical Association. (2023). The Value of Generic Medicines. [41] European Medicines Agency. (2018). Recommendations on NSAIDs and cardiovascular risk. [42] The Economist Intelligence Unit. (2023). Future of Pharmaceutical R&D. [43] Pharmaceutical Executive. (2022). Challenges in Novel Drug Formulation. [44] McKinsey & Company. (2023). Navigating Supply Chain Disruptions. [45] Statista. (2023). Pharmaceutical Market in Emerging Economies. [46] Journal of Controlled Release. (2022). Advances in Drug Delivery Technologies. [47] Chemical & Engineering News. (2023). API Manufacturing Landscape. [48] Contract Pharma. (2023). The Growth of Contract Manufacturing Organizations. [49] Drug Repurposing Research. (2021). Current Trends and Future Prospects.